Steadymed (NASDAQ:STDY)‘s stock had its “buy” rating reaffirmed by equities researchers at JMP Securities in a report issued on Wednesday.
Steadymed (STDY) opened at $3.50 on Wednesday. Steadymed has a one year low of $2.25 and a one year high of $9.70. The firm has a market cap of $88.96 and a P/E ratio of -3.37.
Institutional investors have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP purchased a new stake in Steadymed in the 2nd quarter worth approximately $1,251,000. Nexthera Capital LP increased its holdings in Steadymed by 6,579.5% in the 2nd quarter. Nexthera Capital LP now owns 360,626 shares of the company’s stock worth $2,272,000 after acquiring an additional 355,227 shares in the last quarter. Finally, Kingdon Capital Management L.L.C. purchased a new stake in Steadymed in the 2nd quarter worth approximately $3,170,000. 56.33% of the stock is owned by institutional investors.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/01/12/steadymed-stdy-stock-rating-reaffirmed-by-jmp-securities.html.
Steadymed Company Profile
SteadyMed Ltd. is a specialty pharmaceutical company. The Company is focused on the development and commercialization of various therapeutic product candidates. Its primary focus is to obtain approval in the United States for the sale of Trevyent for the treatment of pulmonary arterial hypertension (PAH).
Receive News & Ratings for Steadymed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steadymed and related companies with MarketBeat.com's FREE daily email newsletter.